EMA CHMP Chair Re-elected
Tomas Salmonson is re-elected as Chair of the Committee for Medicinal Products for Human Use.
The European Medicines Agency (EMA) announced on Sept. 21, 2015 that Dr. Tomas Salmonson has been re-elected as Chair of the Committee for Medicinal Products for Human Use (CHMP). Salmonson is senior scientific advisor at the Swedish Medical Products Agency, has been a member of CHMP for more than 15 years, and has served as CHMP chair for the past three years.
According to an EMA press release, in his second term, Salmonson plans on deepening stakeholder collaboration, facilitating the development of and access to innovative medicines, and improving benefit-risk methodologies.
In response to his re-election, Salmonson stated, “It is a great honor for me to receive the backing of my peers for another term. I have a deep respect and appreciation for the work of the dedicated and professional members of the Committee. CHMP is a forum for open discussion. Debate between members with different backgrounds and views is an essential element in delivering robust scientific opinions. I look forward to working even harder to maintain and strengthen this fruitful working environment in order to fulfill our public health mandate.”
Source: European Medicines Agency
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
